| 國立成功大學 |
2023 |
Na-Intercalation Compounds and Na-Ion Batteries
|
Chung, H.-C.;Li, W.-B.;Wang, Y.-M.;Lin, M.-F. |
| 國立成功大學 |
2023 |
Energy Resources and Challenges
|
Nguyen, T.D.H.;Li, W.-B.;Dien, V.K.;Han, N.T.;Chung, H.-C.;Lin, S.-Y.;Thuan, L.V.P.;Tran, N.T.T.;Shih, J.-H.;Lin, M.-F. |
| 臺大學術典藏 |
2022-09-15T01:08:50Z |
Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: The PACT phase Ia/Ib trial
|
Patnaik A.; Yap T.A.; Chung H.C.; de Miguel M.J.; Bang Y.-J.; Chia-Chi Lin; Su W.-C.; Italiano A.; Chow K.H.; Szpurka A.M.; Yu D.; Zhao Y.; Carlsen M.; Schmidt S.; Vangerow B.; Gandhi L.; Xu X.; Bendell J. |
| 臺大學術典藏 |
2022-09-15T01:08:49Z |
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia
|
Chia-Chi Lin; Doi T.; Muro K.; Hou M.-M.; Esaki T.; Hara H.; Chung H.C.; Helwig C.; Dussault I.; Osada M.; Kondo S. |
| 臺大學術典藏 |
2022-09-15T01:08:45Z |
Safety and Antitumor Activity of a-PD-L1 Antibody as Monotherapy or in Combination witha-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors
|
Hollebecque A.; Chung H.C.; Miguel M.J.D.; Italiano A.; MacHiels J.-P.; Chia-Chi Lin; Dhani N.C.; Peeters M.; Moreno V.; Su W.-C.; Chow K.H.; Galvao V.R.; Carlse M.; Yu D.; Szpurka A.M.; Zhao Y.; Schmidt S.L.; Gandhi L.; Xu X.; Bang Y.-J. |
| 臺大學術典藏 |
2022-08-19T06:48:44Z |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Chung H.C.; Davis S.L.; Dev A.; Gane E.; George B.; He A.R.; Hochster H.; Hsu C.-H.; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Stein S.; Strickler J.; Tebbutt N.; Chao Y.; Chen J.-S.; Bang Y.-J.; Bendell J.; Lee K.-H.; Wang Y.; Abdullah H.; Liu B.; Spahn J.; Hack S.P.; Verret W.; CHIH-HUNG HSU; Lee M.S. |
| 臺大學術典藏 |
2022-08-19T00:20:33Z |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Tebbutt N.; Strickler J.; Stein S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Gane E.; George B.; He A.R.; Hochster H.; CHIUN HSU; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Dev A.; Davis S.L.; Chung H.C.; Chen J.-S.; Chao Y.; Bendell J.; Bang Y.-J.; Lee K.-H.; He A.R.; Wang Y.; Liu B.; Abdullah H.; Hack S.P.; Spahn J.; Lee M.S.; Ryoo B.-Y.; Hsu C.-H.; Numata K.; Stein S.; Verret W. |
| 臺大學術典藏 |
2022-05-13T08:05:07Z |
Clinical experience of 17 cases of imported malaria at a Taiwan university hospital, 1999-2005
|
Chung H.-C.; JANN-TAY WANG; Sun H.-Y.; Wang J.-L.; Lo Y.-C.; Sheng W.-H.; Hsieh S.-M.; Fang C.-T.; Hsueh P.-R.; Chen Y.-C.; Chang S.-C. |
| 臺大學術典藏 |
2022-03-10T06:14:59Z |
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens
|
Dai M.S.; Feng Y.H.; Chen S.W.; Masuda N.; Yau T.; Chen S.T.; YEN-SHEN LU; Yap Y.S.; Ang P.C.S.; Chu S.C.; Kwong A.; Lee K.S.; Ow S.; Kim S.B.; Lin J.; Chung H.C.; Ngan R.; Kok V.C.; Rau K.M.; Sangai T.; Ng T.Y.; Tseng L.M.; Bryce R.; Bebchuk J.; Chen M.C.; Hou M.F. |
| 臺大學術典藏 |
2022-01-05T03:36:40Z |
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study
|
Kang Y.-K.; Morita S.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Chen L.-T.; Boku N. |
| 臺大學術典藏 |
2022-01-05T03:36:39Z |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
|
Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Nishiyama T.; Chen L.-T.; Kang Y.-K. |
| 國立成功大學 |
2022 |
Compact and robust 2 � 2 fast quasi-adiabatic 3-dB couplers on SOI strip waveguides
|
Hung, Y.-J.;Jr;Chen, Chen C.-H.;Lu, G.-X.;Liang, F.-C.;Chung, H.-C.;Tseng, S.-Y. |
| 國立成功大學 |
2022 |
Compact polarization-independent quasi-adiabatic 2�2 3 dB coupler on silicon
|
Chung, H.-C.;Chen, Chen C.-H.;Hung, Y.-J.;Tseng, S.-Y. |
| 國立成功大學 |
2022 |
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-contr
|
Kang, Y.-K.;Chen, L.-T.;Ryu, M.-H.;Oh, D.-Y.;Oh, S.C.;Chung, H.C.;Lee, K.-W.;Omori, T.;Shitara, K.;Sakuramoto, Sakuramoto S.;Chung, I.-J.;Yamaguchi, K.;Kato, Kato K.;Sym, Sym S.J.;Kadowaki, S.;Tsuji, K.;Chen, J.-S.;Bai, L.-Y.;Oh, S.-Y.;Choda, Y.;Yasui, H.;Takeuchi, K.;Hirashima, Y.;Hagihara, S.;Boku, N. |
| 國立成功大學 |
2022 |
Ultra-broadband Silicon Polarization Independent 3-dB Coupler using Multi-parameter Adiabaticity Engineering
|
Chung, H.-C.;Tseng, S.-Y. |
| 臺大學術典藏 |
2021-12-01T06:02:57Z |
Clinical experience of 17 cases of imported malaria at a Taiwan university hospital, 1999-2005
|
Chung H.-C.; Wang J.-T.; Sun H.-Y.; Wang J.-L.; Lo Y.-C.; Sheng W.-H.; Hsieh S.-M.; Fang C.-T.; Hsueh P.-R.; YEE-CHUN CHEN; Chang S.-C. |
| 臺大學術典藏 |
2021-09-01T01:53:43Z |
Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial
|
ANN-LII CHENG; Kang Y.-K.; Lin D.-Y.; Park J.-W.; Kudo M.; Qin S.; Chung H.-C.; Song X.; Xu J.; Poggi G.; Omata M.; Lowenthal S.P.; Lanzalone S.; Yang L.; Lechuga M.J.; Raymond E. |
| 臺大學術典藏 |
2021-07-26T09:44:38Z |
Digging and burying of hosts by a pupal parasitoid
|
Chung H.-C;Okuyama T.; Chung H.-C; Okuyama T.; TOSHINORI OKUYAMA |
| 臺大學術典藏 |
2021-05-06T01:52:41Z |
Clinical experience of 17 cases of imported malaria at a Taiwan university hospital, 1999-2005
|
Chung H.-C.; Wang J.-T.; Sun H.-Y.; Wang J.-L.; Lo Y.-C.; Sheng W.-H.; Hsieh S.-M.; Fang C.-T.; Hsueh P.-R.; YEE-CHUN CHEN; Chang S.-C. |
| 臺大學術典藏 |
2021-05-03T02:21:02Z |
MiR-103/107 promote metastasis of colorectal cancer by targeting the metastasis suppressors DAPK and KLF4
|
Chen H.-Y.; Lin Y.-M.; Chung H.-C.; Lang Y.-D.; Lin C.-J.; Huang J.; Wang W.-C.; Lin F.-M.; Chen Z.; Huang H.-D.; Shyy J.Y.-J.; JIN-TUNG LIANG; Chen R.-H. |
| 臺大學術典藏 |
2021-04-20T03:46:19Z |
Clinical experience of 17 cases of imported malaria at a Taiwan university hospital, 1999-2005
|
Chung H.-C.; Wang J.-T.; Sun H.-Y.; Wang J.-L.; Lo Y.-C.; Sheng W.-H.; Hsieh S.-M.; CHI-TAI FANG; Hsueh P.-R.; Chen Y.-C.; Chang S.-C. |
| 臺大學術典藏 |
2021-02-26T02:00:17Z |
Clinical experience of 17 cases of imported malaria at a Taiwan university hospital, 1999-2005
|
Chung H.-C.;Wang J.-T.;Sun H.-Y.;Wang J.-L.;Lo Y.-C.;Wang-Huei Sheng;Hsieh S.-M.;Fang C.-T.;Hsueh P.-R.;Chen Y.-C.;Chang S.-C.; Chung H.-C.; Wang J.-T.; Sun H.-Y.; Wang J.-L.; Lo Y.-C.; WANG-HUEI SHENG; Hsieh S.-M.; Fang C.-T.; Hsueh P.-R.; Chen Y.-C.; Chang S.-C. |
| 臺大學術典藏 |
2021-02-19T06:52:27Z |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Lee M.S.;Ryoo B.-Y.;Chih-Hung Hsu;Numata K.;Stein S.;Verret W.;Hack S.P.;Spahn J.;Liu B.;Abdullah H.;Wang Y.;He A.R.;Lee K.-H.;Bang Y.-J.;Bendell J.;Chao Y.;Chen J.-S.;Chung H.C.;Davis S.L.;Dev A.;Gane E.;George B.;He A.R.;Hochster H.;Chih-Hung Hsu;Ikeda M.;Lee J.;Lee M.;Mahipal A.;Manji G.;Morimoto M.;Numata K.;Pishvaian M.;Qin S.;Ryan D.;Ryoo B.-Y.;Sasahira N.;Stein S.;Strickler J.;Tebbutt N.; Lee M.S.; Ryoo B.-Y.; CHIH-HUNG HSU; Numata K.; Stein S.; Verret W.; Hack S.P.; Spahn J.; Liu B.; Abdullah H.; Wang Y.; He A.R.; Lee K.-H.; Bang Y.-J.; Bendell J.; Chao Y.; Chen J.-S.; Chung H.C.; Davis S.L.; Dev A.; Gane E.; George B.; He A.R.; Hochster H.; CHIH-HUNG HSU; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Stein S.; Strickler J.; Tebbutt N. |
| 臺大學術典藏 |
2021-02-18T01:45:22Z |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Lee M.S.;Ryoo B.-Y.;Numata K.;Stein S.;Verret W.;Hack S.P.;Spahn J.;Liu B.;Abdullah H.;Wang Y.;He A.R.;Lee K.-H.;Bang Y.-J.;Bendell J.;Chao Y.;Chen J.-S.;Chung H.C.;Davis S.L.;Dev A.;Gane E.;George B.;He A.R.;Hochster H.;Chiun Hsu;Ikeda M.;Lee J.;Lee M.;Mahipal A.;Manji G.;Morimoto M.;Numata K.;Pishvaian M.;Qin S.;Ryan D.;Ryoo B.-Y.;Sasahira N.;Stein S.;Strickler J.;Tebbutt N.; Lee M.S.; Ryoo B.-Y.; Numata K.; Stein S.; Verret W.; Hack S.P.; Spahn J.; Liu B.; Abdullah H.; Wang Y.; He A.R.; Lee K.-H.; Bang Y.-J.; Bendell J.; Chao Y.; Chen J.-S.; Chung H.C.; Davis S.L.; Dev A.; Gane E.; George B.; He A.R.; Hochster H.; Chiun Hsu; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Stein S.; Strickler J.; Tebbutt N. |
| 臺大學術典藏 |
2021-02-02T00:46:39Z |
A Cullin3-KLHL20 Ubiquitin Ligase-Dependent Pathway Targets PML to Potentiate HIF-1 Signaling and Prostate Cancer Progression
|
Yuan W.-C. ;Lee Y.-R. ;Huang S.-F. ;Lin Y.-M. ;Chen T.-Y. ;Chung H.-C. ;Tsai C.-H. ;Chen H.-Y. ;Chiang C.-T. ;Lai C.-K. ;Lu L.-T. ;Chen C.-H. ;Gu D.-L. ;Yeong-Shiau Pu ;Jou Y.-S. ;Lu K. ;Hsiao P.-W. ;Shih H.-M. ;Chen R.-H.; Yuan W.-C.; Lee Y.-R.; Huang S.-F.; Lin Y.-M.; Chen T.-Y.; Chung H.-C.; Tsai C.-H.; Chen H.-Y.; Chiang C.-T.; Lai C.-K.; Lu L.-T.; Chen C.-H.; Gu D.-L.; YEONG-SHIAU PU; Jou Y.-S.; Lu K.; Hsiao P.-W.; Shih H.-M.; Chen R.-H. |
| 臺大學術典藏 |
2021-01-28T01:06:36Z |
Everolimus for previously treated advanced gastric cancer: Results of the randomized, double-blind, phase III GRANITE-1 study
|
Ohtsu A.;Ajani J.A.;Bai Y.-X.;Bang Y.-J.;Chung H.-C.;Pan H.-M.;Sahmoud T.;Shen L.;Kun-Huei Yeh;Chin K.;Muro K.;Kim Y.H.;Ferry D.;Tebbutt N.C.;Al-Batran S.-E.;Smith H.;Costantini C.;Rizvi S.;Lebwohl D.;Van Cutsem E.; Ohtsu A.; Ajani J.A.; Bai Y.-X.; Bang Y.-J.; Chung H.-C.; Pan H.-M.; Sahmoud T.; Shen L.; KUN-HUEI YEH; Chin K.; Muro K.; Kim Y.H.; Ferry D.; Tebbutt N.C.; Al-Batran S.-E.; Smith H.; Costantini C.; Rizvi S.; Lebwohl D.; Van Cutsem E. |
| 臺大學術典藏 |
2021-01-28T01:06:31Z |
Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN - A randomized, phase III study
|
Satoh T.;Doi T.;Ohtsu A.;Tsuji A.;Omuro Y.;Mukaiyama A.;Kobayashi M.;Miwa H.;Xu R.-H.;Sun G.-P.;Xu J.-M.;Wang J.-W.;Li J.;Qin S.-K.;Feng J.-F.;Chung H.C.;Bang Y.-J.;Chung I.-J.;Kun-Huei Yeh; Satoh T.; Doi T.; Ohtsu A.; Tsuji A.; Omuro Y.; Mukaiyama A.; Kobayashi M.; Miwa H.; Xu R.-H.; Sun G.-P.; Xu J.-M.; Wang J.-W.; Li J.; Qin S.-K.; Feng J.-F.; Chung H.C.; Bang Y.-J.; Chung I.-J.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-28T01:06:21Z |
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Kang Y.-K.;Boku N.;Satoh T.;Ryu M.-H.;Chao Y.;Kato K.;Chung H.C.;Chen J.-S.;Muro K.;Kang W.K.;Kun-Huei Yeh;Yoshikawa T.;Oh S.C.;Bai L.-Y.;Tamura T.;Lee K.-W.;Hamamoto Y.;Kim J.G.;Chin K.;Oh D.-Y.;Minashi K.;Cho J.Y.;Tsuda M.;Chen L.-T.; Kang Y.-K.; Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Chen L.-T. |
| 臺大學術典藏 |
2021-01-28T01:06:20Z |
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYnote-061): a randomised, open-label, controlled, phase 3 trial
|
Shitara K.;?Zg?Ro?Lu M.;Bang Y.-J.;Di Bartolomeo M.;Mandal? M.;Ryu M.-H.;Fornaro L.;Olesi?Ski T.;Caglevic C.;Chung H.C.;Muro K.;Goekkurt E.;Mansoor W.;Mcdermott R.S.;Shacham-Shmueli E.;Chen X.;Mayo C.;Kang S.P.;Ohtsu A.;Fuchs C.S.;Lerzo G.;O'Connor J.M.;Mendez G.A.;Lynam J.;Tebbutt N.;Wong M.;Strickland A.;Karapetis C.;Goldstein D.;Vasey P.;Van Laethem J.-L.;Van Cutsem E.;Berry S.;Vincent M.;Muller B.;Rey F.;Zambrano A.;Guerra J.;Krogh M.;Baeksgaard L.;Yilmaz M.;Elme A.;Magi A.;Auvinen P.;Alanko T.;Moehler M.;Kunzmann V.;Seufferlein T.;Thuss-Patience P.;Goekkurt E.;Hoehler T.;Haag G.;Al-Batran S.-E.;Castro H.;Lopez K.;Aguilar Vasquez M.;Sandoval M.;Lam K.O.;Cuffe S.;Kelly C.;Geva R.;Shacham-Shmueli E.;Hubert A.;Beny A.;Brenner B.;Giuseppe A.;Falcone A.;Maiello E.;Passalacqua R.;Montesarchio V.;Hara H.;Chin K.;Nishina T.;Komatsu Y.;Machida N.;Hironaka S.;Satoh T.;Tamura T.;Sugimoto N.;Cho H.;Omuro Y.;Kato K.;Goto M.;Hyodo I.;Yoshida K.;Baba H.;Esaki T.;Furuse J.;Wan Mohammed W.Z.;Hernandez Hernandez C.;Casas Garcia J.;Dominguez Andrade A.;Clarke K.;Hjortland G.;Glenjen N.;Kubiatowski T.;Jacek J.;Wojtukiewicz M.;Lazarev S.;Lancukhay Y.;Afanasayev S.;Moiseyenko V.;Kostorov V.;Protsenko S.;Shirinkin V.;Sakaeva D.;Fadeeva N.;Yong W.P.;Ng C.H.M.;Robertson B.;Rapaport B.;Cohen G.;Dreosti L.;Ruff P.;Jacobs C.;Landers G.;Szpak W.;Roh S.-Y.;Lee J.;Kim Y.H.;Bang Y.-J.;Chung H.C.;Ryu M.-H.;Alsina Maqueda M.;Longo Munoz F.;Cervantes Aguilar A.;Aranda Aguilar E.;Garcia Alfonso P.;Rivera F.;Feliu Batle J.;Pazo Cid R.;Kun-Huei Yeh;Chen J.-S.;Chao Y.;Yen C.-J.;?Zg?Ro?Lu M.;Kara O.;Yalcin S.;Hochhauser D.;Chau I.;Benson A.;Shankaran V.;Shaib W.;Philip P.;Sharma V.;Siegel R.;Sun W.;Wainberg Z.;George B.;Bullock A.;Myrick S.;Faruol J.;Siegel R.;Larson T.;Becerra C.;Ratnam S.;Richards D.A.;Riche S.L.;Keynote-061 Investigators; Shitara K.; ?zg?ro?lu M.; Bang Y.-J.; Di Bartolomeo M.; Mandal? M.; Ryu M.-H.; Fornaro L.; Olesi?ski T.; Caglevic C.; Chung H.C.; Muro K.; Goekkurt E.; Mansoor W.; McDermott R.S.; Shacham-Shmueli E.; Chen X.; Mayo C.; Kang S.P.; Ohtsu A.; Fuchs C.S.; Lerzo G.; O'Connor J.M.; Mendez G.A.; Lynam J.; Tebbutt N.; Wong M.; Strickland A.; Karapetis C.; Goldstein D.; Vasey P.; Van Laethem J.-L.; Van Cutsem E.; Berry S.; Vincent M.; Muller B.; Rey F.; Zambrano A.; Guerra J.; Krogh M.; Baeksgaard L.; Yilmaz M.; Elme A.; Magi A.; Auvinen P.; Alanko T.; Moehler M.; Kunzmann V.; Seufferlein T.; Thuss-Patience P.; Goekkurt E.; Hoehler T.; Haag G.; Al-Batran S.-E.; Castro H.; Lopez K.; Aguilar Vasquez M.; Sandoval M.; Lam K.O.; Cuffe S.; Kelly C.; Geva R.; Shacham-Shmueli E.; Hubert A.; Beny A.; Brenner B.; Giuseppe A.; Falcone A.; Maiello E.; Passalacqua R.; Montesarchio V.; Hara H.; Chin K.; Nishina T.; Komatsu Y.; Machida N.; Hironaka S.; Satoh T.; Tamura T.; Sugimoto N.; Cho H.; Omuro Y.; Kato K.; Goto M.; Hyodo I.; Yoshida K.; Baba H.; Esaki T.; Furuse J.; Wan Mohammed W.Z.; Hernandez Hernandez C.; Casas Garcia J.; Dominguez Andrade A.; Clarke K.; Hjortland G.; Glenjen N.; Kubiatowski T.; Jacek J.; Wojtukiewicz M.; Lazarev S.; Lancukhay Y.; Afanasayev S.; Moiseyenko V.; Kostorov V.; Protsenko S.; Shirinkin V.; Sakaeva D.; Fadeeva N.; Yong W.P.; Ng C.H.M.; Robertson B.; Rapaport B.; Cohen G.; Dreosti L.; Ruff P.; Jacobs C.; Landers G.; Szpak W.; Roh S.-Y.; Lee J.; Kim Y.H.; Bang Y.-J.; Chung H.C.; Ryu M.-H.; Alsina Maqueda M.; Longo Munoz F.; Cervantes Aguilar A.; Aranda Aguilar E.; Garcia Alfonso P.; Rivera F.; Feliu Batle J.; Pazo Cid R.; KUN-HUEI YEH; Chen J.-S.; Chao Y.; Yen C.-J.; ?zg?ro?lu M.; Kara O.; Yalcin S.; Hochhauser D.; Chau I.; Benson A.; Shankaran V.; Shaib W.; Philip P.; Sharma V.; Siegel R.; Sun W.; Wainberg Z.; George B.; Bullock A.; Myrick S.; Faruol J.; Siegel R.; Larson T.; Becerra C.; Ratnam S.; Richards D.A.; Riche S.L.; KEYnote-061 investigators |
| 臺大學術典藏 |
2021-01-28T01:06:16Z |
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
|
Chen L.-T.;Satoh T.;Ryu M.-H.;Chao Y.;Kato K.;Chung H.C.;Chen J.-S.;Muro K.;Kang W.K.;Kun-Huei Yeh;Yoshikawa T.;Oh S.C.;Bai L.-Y.;Tamura T.;Lee K.-W.;Hamamoto Y.;Kim J.G.;Chin K.;Oh D.-Y.;Minashi K.;Cho J.Y.;Tsuda M.;Sameshima H.;Kang Y.-K.;Boku N.; Chen L.-T.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Kang Y.-K.; Boku N. |
| 國立成功大學 |
2021 |
Safety and Antitumor Activity of a-PD-L1 Antibody as Monotherapy or in Combination witha-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors
|
Hollebecque, A.;Chung, H.C.;Miguel, Miguel M.J.D.;Italiano, A.;MacHiels, J.-P.;Lin, C.-C.;Dhani, N.C.;Peeters, M.;Moreno, V.;Su, W.-C.;Chow, K.H.;Galvao, V.R.;Carlse, M.;Yu, D.;Szpurka, A.M.;Zhao, Y.;Schmidt, Schmidt S.L.;Gandhi, L.;Xu, Xu X.;Bang, Y.-J. |
| 國立成功大學 |
2021 |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
|
Boku, N.;Satoh, T.;Ryu, M.-H.;Chao, Y.;Kato, Kato K.;Chung, H.C.;Chen, J.-S.;Muro, K.;Kang, W.K.;Yeh, K.-H.;Yoshikawa, T.;Oh, S.C.;Bai, L.-Y.;Tamura, Tamura T.;Lee, K.-W.;Hamamoto, Y.;Kim, J.G.;Chin, K.;Oh, D.-Y.;Minashi, K.;Cho, J.Y.;Tsuda, M.;Nishiyama, T.;Chen, L.-T.;Kang, Y.-K. |
| 國立成功大學 |
2021 |
Ultra-Broadband Silicon Polarization Splitter-Rotator using Adiabaticity Engineering
|
Chung, H.-C.;Lu, G.-X.;Tseng, S.-Y. |
| 國立成功大學 |
2021 |
Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: The PACT phase Ia/Ib trial
|
Patnaik, A.;Yap, T.A.;Chung, H.C.;de, Miguel M.J.;Bang, Y.-J.;Lin, C.-C.;Su, W.-C.;Italiano, A.;Chow, K.H.;Szpurka, A.M.;Yu, D.;Zhao, Y.;Carlsen, M.;Schmidt, Schmidt S.;Vangerow, B.;Gandhi, L.;Xu, Xu X.;Bendell, J. |
| 臺大學術典藏 |
2020-12-29T06:37:37Z |
Clinical experience of 17 cases of imported malaria at a Taiwan university hospital, 1999-2005
|
Chang S.-C.; Hsueh P.-R.; Chen Y.-C.; Fang C.-T.; SZU-MIN HSIEH; Sheng W.-H.; Lo Y.-C.; Wang J.-L.; Wang J.-T.; Sun H.-Y.; Chung H.-C. |
| 臺大學術典藏 |
2020-12-29T03:09:21Z |
Clinical experience of 17 cases of imported malaria at a Taiwan university hospital, 1999-2005
|
Chung H.-C.; JANN-TAY WANG; Sun H.-Y.; Wang J.-L.; Lo Y.-C.; Sheng W.-H.; Hsieh S.-M.; Fang C.-T.; Hsueh P.-R.; Chen Y.-C.; Chang S.-C.; Chung H.-C.;Jann-Tay Wang;Sun H.-Y.;Wang J.-L.;Lo Y.-C.;Sheng W.-H.;Hsieh S.-M.;Fang C.-T.;Hsueh P.-R.;Chen Y.-C.;Chang S.-C. |
| 臺大學術典藏 |
2020-12-18T08:39:17Z |
Clinical experience of 17 cases of imported malaria at a Taiwan university hospital, 1999-2005
|
Chang S.-C.; Chen Y.-C.; Fang C.-T.; PO-REN HSUEH; Hsieh S.-M.; Sheng W.-H.; Lo Y.-C.; Wang J.-L.; Sun H.-Y.; Wang J.-T.; Chung H.-C. |
| 臺大學術典藏 |
2020-12-18T08:39:14Z |
Liver abscess due to Neisseria sicca after repeated transcatheter arterial embolization
|
Teng L.-J.; Chung H.-C.; Chung H.-C.;Teng L.-J.;Po-Ren Hsueh; PO-REN HSUEH |
| 臺大學術典藏 |
2020-09-30T03:23:00Z |
Extremely high prevalence and genetic diversity of hepatitis C virus infection among HIV-infected injection drug users in Taiwan
|
Ko W.-C.; Huang C.-K.; Lai C.-H.; Chen Y.-S.; Shih Y.-L.; Chung H.-C.; Liang S.-H.; Lin J.-N.; Liu J.-Y.; Lin H.-H.; Liu Y.-C.; Lee S.S.-J.; Chen Y.-L.; CHIEN-CHING HUNG |
| 臺大學術典藏 |
2020-09-29T01:48:04Z |
Clinical experience of 17 cases of imported malaria at a Taiwan university hospital, 1999-2005
|
Hsueh P.-R.; Fang C.-T.; Hsieh S.-M.; Sheng W.-H.; Lo Y.-C.; Wang J.-L.; Sun H.-Y.; Wang J.-T.; Chung H.-C.; Chung H.-C.;Wang J.-T.;Sun H.-Y.;Wang J.-L.;Lo Y.-C.;Sheng W.-H.;Hsieh S.-M.;Fang C.-T.;Hsueh P.-R.;Yee-Chun Chen;Chang S.-C.; YEE-CHUN CHEN; Chang S.-C. |
| 臺大學術典藏 |
2020-08-13T06:33:32Z |
Ramucirumab safety in East Asian patients: A meta-analysis of six global, randomized, double-blind, placebo-controlled, phase III clinical trials
|
Zhang Y.; Sohn J.; Cheng R.; Yamazaki K.; Kim S.-W.; Chao Y.; Lee K.-W.; JIN-YUAN SHIH; Kudo M.; Kim T.-W.; Muro K.; Yen C.-J.; Yen C.-J.;Muro K.;Kim T.-W.;Kudo M.;Jin-Yuan Shih;Lee K.-W.;Chao Y.;Kim S.-W.;Yamazaki K.;Sohn J.;Cheng R.;Zhang Y.;Binder P.;Mi G.;Orlando M.;Chung H.C.; Binder P.; Mi G.; Orlando M.; Chung H.C. |
| 臺大學術典藏 |
2020-06-30T06:13:36Z |
Liver abscess due to Neisseria sicca after repeated transcatheter arterial embolization
|
Chung H.-C.; LEE-JENE TENG; Hsueh P.-R. |
| 臺大學術典藏 |
2020-06-30T02:49:15Z |
Exercise training for non-operative and post-operative patient with cervical radiculopathy: A literature review
|
Cheng C.-H.;Tsai L.-C.;Chung H.-C.;Wei-Li Hsu;Wang S.-F.;Wang J.-L.;Lai D.-M.;Chien A.; Cheng C.-H.; Tsai L.-C.; Chung H.-C.; WEI-LI HSU; Wang S.-F.; Wang J.-L.; Lai D.-M.; Chien A. |
| 臺大學術典藏 |
2020-06-26T08:33:57Z |
Evaluation of the low cost telemedicine system in Taiwan
|
Jer-Junn Luh;Cheng P.H.;Chen S.J.;Lai J.S.;Chen H.S.;Chung H.C.; JER-JUNN LUH; Cheng P.H.; Chen S.J.; Lai J.S.; Chen H.S.; Chung H.C. |
| 臺大學術典藏 |
2020-05-25T07:35:18Z |
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
|
McRee A.J; Chia-Chi Lin; Pathiraja K; Lunceford J; Emancipator K; Juco J; Koshiji M; Bang Y.-J.; Bang Y.-J.;Koshiji M;Juco J;Emancipator K;Lunceford J;Pathiraja K;Chia-Chi Lin;McRee A.J;Burtness B;Le D.T;Golan T;Eder J.P;Gupta S;Catenacci D;Geva R;Shankaran V;Chung H.C;Muro K; Muro K; Chung H.C; Shankaran V; Geva R; Catenacci D; Gupta S; Eder J.P; Golan T; Le D.T; Burtness B |
| 臺大學術典藏 |
2020-05-25T07:35:17Z |
Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohort
|
Seiwert T.Y.; Cheng J.D; Pathiraja K; Dolled-Filhart M; Meister A; Chung H.C; Chow L.Q.M; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder J.P; Burtness B; Lee S.-H; Keam B; Kang H; Muro K; Weiss J; Geva R; Chia-Chi Lin |
| 臺大學術典藏 |
2020-05-25T07:35:12Z |
Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012
|
Tahara M; Muro K; Hasegawa Y; Chung H.C; Chia-Chi Lin; Keam B; Takahashi K; Cheng J.D; Bang Y.-J. |
| 臺大學術典藏 |
2020-05-25T07:35:10Z |
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: Pooled analyses after long-term follow-up in KEYNOTE-012
|
Cheng J; Chow L.Q.M; Haddad R.; Pathiraja K; Aurora-Garg D; Ray A; Chia-Chi Lin; Chung H.C; Geva R; Mehra R; Seiwert T.Y; Gupta S; Weiss J; Gluck I; Eder J.P; Burtness B; Tahara M; Keam B; Kang H; Muro K |
| 臺大學術典藏 |
2020-05-25T07:35:08Z |
Phase I study results from an esophageal squamous cell carcinoma (ESCC) cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor �] (TGF-�]) and PD-L1
|
Chia-Chi Lin; Doi T; Muro K; Hou M.-M; Esaki T; Hara H; Chung H.-C; Osada M; Helwig C; Kondo S. |
| 臺大學術典藏 |
2020-03-27T05:30:26Z |
Clinical experience of 17 cases of imported malaria at a Taiwan university hospital, 1999-2005
|
Chang S.-C.;Chen Y.-C.;PO-REN HSUEH;Fang C.-T.;Hsieh S.-M.;Sheng W.-H.;Lo Y.-C.;Wang J.-L.;Sun H.-Y.;Wang J.-T.;Chung H.-C.; Chung H.-C.; Wang J.-T.; Sun H.-Y.; Wang J.-L.; Lo Y.-C.; Sheng W.-H.; Hsieh S.-M.; Fang C.-T.; PO-REN HSUEH; Chen Y.-C.; Chang S.-C. |
